Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"

被引：1
|
作者：
Sullivan, Ivana [1 ]
Planchard, David [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, 114 Rue Edouard Vaillant, F-94800 Villejuif, France
来源：
JOURNAL OF THORACIC DISEASE | 2016年 / 8卷 / 10期
关键词：
ADULT PATIENTS PTS; ALK-INHIBITOR; CONFER RESISTANCE; SINGLE-ARM; OPEN-LABEL; CRIZOTINIB; NSCLC; CERITINIB; CHEMOTHERAPY; MUTATIONS;
D O I：
10.21037/jtd.2016.10.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1287 / E1292
页数：6
相关论文
共 50 条
  • [1] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [2] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [4] Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
    Bazhenova, A.
    Gettinger, S. N.
    Langer, C. J.
    Salgia, R.
    Gold, K. A.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Haney, J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
    Wakelee, H.
    Reckamp, K.
    Leal, T.
    Chiappori, A.
    Waqar, S.
    Zeman, K.
    Neal, J.
    Liang, C.
    Harrow, K.
    Holzhausen, A.
    Zhou, J.
    Selvaggi, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S566 - S566
  • [7] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather
    Carter, Corey A.
    Gockerman, Jon P.
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S36 - S37
  • [8] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Lovly, Christine M.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Reckamp, Karen
    Wakelee, Heather
    Carter, Corey A.
    VVagar, Saiama N.
    Neal, Joel
    Gockerman, Jon P.
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    CANCER RESEARCH, 2016, 76
  • [9] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214
  • [10] Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC) refractory to alectinib
    Ou, S-H. I.
    Nishio, M.
    Yoshida, T.
    Ahn, M-J.
    Mok, T. S. K.
    Kudou, K.
    Asato, T.
    Yang, H.
    Tong, X.
    Zhang, P.
    Yamamoto, N.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1015
12345